Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

And van Goor, who has led development of CF drugs at Vertex since 2001 has warned that there is still much work to do to find ways to correct all the different mutations that lead to the disease.

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...